摘要 |
This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R<SUB>1</SUB>, R<SUB>2</SUB>, R<SUB>3</SUB>, and R<SUB>4 </SUB>are each H, alkyl, , alkanoyl, halo, OH, aryl optionally substituted with R<SUB>8</SUB>, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, pertluoroalkoxy; R<SUB>5 </SUB>is H, alkyl, perfluoroalkyl, aryl optionally substituted with R<SUB>5</SUB>, alkanoyl, aroyl optionally substituted with R<SUB>8</SUB>; R<SUB>6 </SUB>is H, alkyl, alkylaryl, benzyl optionally substituted with R<SUB>8</SUB>, alkanoyl, aroyl optionally substituted with R<SUB>8</SUB>; R<SUB>7 </SUB>is H, alkyl, alkylaryl, aryl optionally substituted with R<SUB>8</SUB>; n is 0 - 6 ; A is COOH, or an acid mimic such as tetraazole, SO<SUB>3</SUB>H, PO<SUB>3</SUB>H<SUB>2</SUB>, tetronic acid, etc.; R<SUB>8 </SUB>is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.
|